Nasdaq · Healthcare
LIGAND PHARMACEUTICALS INC (LGND)
As-reported financials and recent SEC filings for LIGAND PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$268.1M
Net income
$124.5M
Net margin
46.4%
Diluted EPS
$6.13
ROE
12.2%
P/E (TTM)
39.5×
Market cap
$6.08B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $241.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $41.0M | $-22.6M | $11.9M | $3.0M | $103.9M |
| Net income | $124.5M | $-4.0M | $52.2M | $-33.4M | $57.1M |
| Diluted EPS | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-25
View on EDGAR →8-K2026-06-22
View on EDGAR →42026-06-18
View on EDGAR →1442026-06-16
View on EDGAR →42026-06-15
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →1442026-06-12
View on EDGAR →Go deeper on LGND
Search LIGAND PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.